SCHEMBL994790

SCHEMBL994790

CC(O)C(C)[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5500004 1.00
SCHEMBL1483243 0.76
SCHEMBL61233 0.72
SCHEMBL1950819 0.72
SCHEMBL4217446 0.72
SCHEMBL10697152 0.71
SCHEMBL269360 0.69
SCHEMBL5199100 0.69
SCHEMBL28497357 0.69
SCHEMBL5840281 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3119895-A1 GENOME EDITING WITHOUT NUCLEASES The Board of Trustees of the Leland Stanford Junior University (US) 2017-01-25 EP claimed
WO-2015143177-A1 GENOME EDITING WITHOUT NUCLEASES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-09-24 WO claimed
EP-2449488-B1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES BIOCRATES LIFE SCIENCES AG (AT) 2015-01-14 EP claimed
US-20120208282-A1 Method For Normalization in Metabolomics Analysis Methods with Endogenous Reference Metabolites. BIOCRATES LIFE SCIENCES AG 2012-08-16 US claimed
EP-2449488-A1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES BIOCRATES Life Sciences AG (AT) 2012-05-09 EP claimed
WO-2011000753-A1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES BIOCRATES LIFE SCIENCES AG (AT) 2011-01-06 WO claimed
EP-2270699-A1 Method for normalization in metabolomics analysis methods with endogenous reference metabolites BIOCRATES Life Sciences AG (AT) 2011-01-05 EP claimed
EP-1754700-A2 Synthesis of oligoketides Kosan Biosciences, Inc. (US) 2007-02-21 EP claimed
US-20030096374-A1 Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer ASHLEY GARY (US) 2003-05-22 US claimed
US-20030092140-A1 Novel polyketides and antibiotics ASHLEY GARY (US) 2003-05-15 US claimed
JP-2002535387-A 2002-10-22 JP claimed
EP-1144375-A2 SYNTHESIS OF OLIGOKETIDES Kosan Biosciences (US) 2001-10-17 EP claimed
WO-2000044717-A9 SYNTHESIS OF OLIGOKETIDES 2001-08-23 WO claimed
EP-1098630-A2 COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION Biomed Research and Technologies, Inc. (US) 2001-05-16 EP claimed
WO-2000044717-A2 SYNTHESIS OF OLIGOKETIDES KOSAN BIOSCIENCES, INC. (US) 2000-08-03 WO claimed
WO-2000004870-A2 COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) 2000-02-03 WO claimed
JP-62207288-A None JP disclosed
EP-2771696-B1 METHODS MAKING USE OF PANELS OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY INFANDX AG (DE) 2022-09-14 EP disclosed
WO-1993020805-A1 CHEMICAL PREVENTION OR REVERSAL OF CATARACT BY PHASE SEPARATION INHIBITORS OCULON CORPORATION (US) 1993-10-28 WO disclosed
JP-S62207288-A ROSIN GLUCOSIDE AND PRODUCTION THEREOF WAKUNAGA PHARMACEUT CO LTD 1987-09-11 JP disclosed